阿托伐他汀与安慰剂在重症监护室新冠患者中的随机对照试验
INSPIRATION-S 试验在伊朗 11 家医院将 605 例 ICU 新冠患者随机分配至阿托伐他汀 20 mg 每日一次组或安慰剂组,主要疗效终点为 30 天内静脉或动脉血栓、体外膜氧合治疗或全因死亡的复合终点。587 例纳入主要分析(阿托伐他汀组 290 例,安慰剂组 297 例),主要终点发生率阿托伐他汀组 33% vs 安慰剂组 36%(OR 0.84,95%CI 0.58-1.21),差异无统计学意义;治疗安全性良好。由于总体事件率低于预期,不能排除具有临床意义的治疗效应。
要点
- ICU 新冠患者中,阿托伐他汀 20 mg 每日一次未显著降低 30 天血栓、ECMO 或全因死亡复合终点(OR 0.84,95%CI 0.58-1.21)。
- 阿托伐他汀组死亡 31% vs 安慰剂组 35%(OR 0.84,95%CI 0.58-1.22),差异无统计学意义。
- 治疗安全性良好,肌病两组均未临床诊断,肝酶升高超过正常上限 3 倍者阿托伐他汀组 2% vs 安慰剂组 2%(OR 0.85,95%CI 0.25-2.81)。
核心结论
- 在 ICU 成人新冠患者中,与安慰剂相比,阿托伐他汀未显著降低静脉或动脉血栓、体外膜氧合治疗或全因死亡的复合终点。
- 治疗被认为是安全的。
- 由于总体事件率低于预期,不能排除具有临床意义的治疗效应。
研究设计与样本
- INSPIRATION/INSPIRATION-S 为多中心、随机对照试验,采用 2×2 析因设计,抗凝随机化结果此前已报告,本文报告双盲随机分配阿托伐他汀与安慰剂的结果。
- 研究在伊朗 11 家医院进行,纳入年龄≥18 岁入住 ICU 的 covid-19 成人患者。
- 干预为阿托伐他汀 20 mg 口服每日一次 versus 安慰剂,从随机化起持续 30 天,不论出院状态。
- 605 例患者于 2020 年 7 月 29 日至 2021 年 4 月 4 日随机分配至他汀组,其中 343 例与中间剂量 versus 标准剂量预防性肝素抗凝共同随机,262 例在抗凝研究完成后随机。
- 605 例中 587 例纳入主要分析:阿托伐他汀组 290 例,安慰剂组 297 例;中位年龄 57 岁(四分位距 45-68 岁),女性 256 例(44%)。
主要发现
- 主要疗效终点为随机化后 30 天内静脉或动脉血栓、体外膜氧合治疗或全因死亡的复合终点,阿托伐他汀组 95 例(33%)vs 安慰剂组 108 例(36%),OR 0.84,95%CI 0.58-1.21。
- 死亡:阿托伐他汀组 90 例(31%)vs 安慰剂组 103 例(35%),OR 0.84,95%CI 0.58-1.22。
- 静脉血栓栓塞:阿托伐他汀组 2%(n=6)vs 安慰剂组 3%(n=9),OR 0.71,95%CI 0.24-2.06。
- 肌病:两组均未临床诊断。
- 肝酶升高超过正常上限 3 倍:阿托伐他汀组 5 例(2%)vs 安慰剂组 6 例(2%),OR 0.85,95%CI 0.25-2.81。
临床怎么用
- 原文未据此给出推荐。
局限性
- 由于总体事件率低于预期,不能排除具有临床意义的治疗效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the effect of statin treatment versus placebo on clinical outcomes in patients with covid-19 admitted to the intensive care unit (ICU). DESIGN: INSPIRATION/INSPIRATION-S was a multicenter, randomized controlled trial with a 2×2 factorial design. Results for the anticoagulation randomization have been reported previously. Results for the double blind randomization to atorvastatin versus placebo are reported here. SETTING: 11 hospitals in Iran. PARTICIPANTS: Adults aged ≥18 years with covid-19 admitted to the ICU. INTERVENTION: Atorvastatin 20 mg orally once daily versus placebo, to be continued for 30 days from randomization irrespective of hospital discharge status. MAIN OUTCOME MEASURES: The primary efficacy outcome was a composite of venous or arterial thrombosis, treatment with extracorporeal membrane oxygenation, or all cause mortality within 30 days from randomization. Prespecified safety outcomes included increase in liver enzyme levels more than three times the upper limit of normal and clinically diagnosed myopathy. A clinical events committee blinded to treatment assignment adjudicated the efficacy and safety outcomes. RESULTS: Of 605 patients randomized between 29 July 2020 and 4 April 2021 for statin randomization in the INSPIRATION-S trial, 343 were co-randomized to intermediate dose versus standard dose prophylactic anticoagulation with heparin based regimens, whereas 262 were randomized after completion of the anticoagulation study. 587 of the 605 participants were included in the primary analysis of INSPIRATION-S, reported here: 290 were assigned to atorvastatin and 297 to placebo (median age 57 years (interquartile range 45-68 years); 256 (44%) women). The primary outcome occurred in 95 (33%) patients assigned to atorvastatin and 108 (36%) assigned to placebo (odds ratio 0.84, 95% confidence interval 0.58 to 1.21). Death occurred in 90 (31%) patients in the atorvastatin group and 103 (35%) in the placebo group (odds ratio 0.84, 95% confidence interval 0.58 to 1.22). Rates for venous thromboembolism were 2% (n=6) in the atorvastatin group and 3% (n=9) in the placebo group (odds ratio 0.71, 95% confidence interval 0.24 to 2.06). Myopathy was not clinically diagnosed in either group. Liver enzyme levels were increased in five (2%) patients assigned to atorvastatin and six (2%) assigned to placebo (odds ratio 0.85, 95% confidence interval 0.25 to 2.81). CONCLUSIONS: In adults with covid-19 admitted to the ICU, atorvastatin was not associated with a significant reduction in the composite of venous or arterial thrombosis, treatment with extracorporeal membrane oxygenation, or all cause mortality compared with placebo. Treatment was, however, found to be safe. As the overall event rates were lower than expected, a clinically important treatment effect cannot be excluded. TRIAL REGISTRATION: ClinicalTrials.gov NCT04486508.
引用
- Atorvastatin versus placebo in patients with covid-19 in intensive care: randomized controlled trial. BMJ. 2022. PMID: 34996756. doi:10.1136/bmj-2021-068407
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。